Roche Reports Positive Data
Roche Holdings Ltd. (RHHBY) reported positive data from a mid-stage trial on trastuzumab emtansine (T-DM1) in treatment-naïve patients with HER2-positive metastatic breast cancer. The phase II trial (TDM4450g) compared trastuzumab emtansine with the combination of Herceptin (trastuzumab) and chemotherapy (docetaxel). The trial results demonstrated that treatment with trastuzumab emtansine led to a 41% decline in [...]
Roche Holdings Ltd. (RHHBY) reported positive data from a mid-stage trial on trastuzumab emtansine (T-DM1) in treatment-naïve patients with HER2-positive metastatic breast cancer. The phase II trial (TDM4450g) compared trastuzumab emtansine with the combination of Herceptin (trastuzumab) and chemotherapy (docetaxel).
The trial results demonstrated that treatment with trastuzumab emtansine led to a 41% decline in the risk of disease worsening or death in patients in the trastuzumab emtansine … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards